XML 71 R57.htm IDEA: XBRL DOCUMENT v3.25.1
Research and Development Expense (Details Narrative) - USD ($)
 12 Months Ended
Oct. 11, 2024
Oct. 09, 2024
Jun. 24, 2024
Aug. 31, 2023
Dec. 31, 2024
Dec. 31, 2023
Proceeds from issuance of common shares related to ATM program         $ 3,328,000
Issuance of Common Stock for licensing right, shares 11,380          
General and Administrative Expense         12,041,000 5,172,000
Research and Development Expense         3,378,000 90,000
Issuance of Common Stock for licensing right   $ 100,000     1,568,000  
Amortization         $ 1,666,000 $ 479,000
Common Stock [Member]            
Issuance of Common Stock for licensing right, shares   20,000 961 65,000,000 125,000  
Issuance of Common Stock for licensing right   $ 80,000     $ 1,000  
SARBORG Service Agreement [Member]            
Cash payment         200,000  
Payable in cash         1,800,000  
SARBORG Service Agreement [Member] | Research and Development Expense [Member]            
Amortization         $ 200,000  
SARBORG Service Agreement [Member] | Common Stock [Member]            
Issuance of Common Stock for licensing right, shares         22,727  
Issuance of Common Stock for licensing right         $ 200,000  
Astra Zeneca [Member]            
Proceeds from issuance of common shares related to ATM program         $ 1,500,000  
Issuance of Common Stock for licensing right, shares         95,044  
General and Administrative Expense         $ 1,600,000  
Research and Development Expense         $ 1,500,000